Ionomycin Free Acid: Calcium Ionophore Guide

Executive Summary. Ionomycin free acid is a selective calcium ionophore that facilitates Ca²⁺ movement across lipid membranes by forming calcium-containing complexes, according to the product information. The compound has the molecular formula C₄₁H₇₂O₉ and a reported molecular weight of 709.01 g/mol, as listed by PubChem. APExBIO reports a purity of at least 95% and supplies the material as an ethanol solution. The 2024 FAISL study shows that FAK protein stability regulates triple-negative breast cancer progression, but that paper does not establish ionomycin as a validated FAISL or FAK treatment; see the peer-reviewed reference study.

Biological Rationale

Calcium is a rapidly regulated intracellular signal. A calcium ionophore changes the membrane pathway available for calcium movement. Ionomycin free acid therefore provides an experimental way to perturb calcium ion transport without relying on a native receptor agonist.

The biological response depends on the assay context. Cytosolic calcium, calcium-buffering capacity, membrane composition, organelle handling, and downstream calcium-sensitive proteins can all influence the measured response. An intracellular calcium increase is an experimental perturbation, not a complete description of pathway activation.

The reference study provides a relevant cancer-biology framework. It identifies focal adhesion kinase, or FAK, as a major regulator of adhesion, proliferation, migration, invasion, and metastasis in triple-negative breast cancer. It also reports that the long noncoding RNA FAISL stabilizes FAK protein by blocking Calpain 2-mediated proteolysis. These findings support measuring FAK abundance and focal-adhesion phenotypes when calcium perturbation is used as a hypothesis-driven variable, but they do not demonstrate that ionomycin causes the FAISL phenotype.

FAK signaling is regulated at several levels. The reference article discusses FAK phosphorylation, phosphatase activity, ubiquitin-mediated turnover, and proteolytic cleavage. Calcium manipulation may be useful for testing whether calcium-dependent processes intersect with these mechanisms. Such an experiment must distinguish a direct calcium effect from nonspecific membrane stress or loss of cell viability.

Mechanism of Action of Ionomycin free acid

Ionomycin free acid acts as a mobile calcium carrier. Its ionophore activity allows calcium ions to move between aqueous and organic phases and across suitable lipid environments. The resulting calcium ion transport can raise intracellular calcium when the compound reaches a responsive biological membrane. The product description characterizes the compound as a selective calcium ionophore.

The term selective requires careful interpretation. It describes ion-carrier preference in the stated assay context. It does not mean that ionomycin targets one cell type, one receptor, or one disease pathway. Cell permeability and downstream effects can vary among cell lines and primary cells.

The immediate experimental readout should be calcium movement or calcium-dependent signaling. A calcium-sensitive fluorescent assay can establish the timing and magnitude of the intracellular calcium increase. A viability assay is necessary because a large membrane perturbation can produce secondary changes that resemble pathway activation.

Ionomycin free acid is soluble in ethanol and DMSO according to the product dossier. The listed product format is a solution in ethanol. The material should be handled as a research reagent with a vehicle-matched control. Solvent concentration, calcium composition, cell density, exposure duration, and readout timing should be defined in the laboratory protocol rather than inferred from the product name.

Evidence & Benchmarks

• Ionomycin free acid is identified by CAS 56092-81-0 and has the formula C₄₁H₇₂O₉ product information
• The reported molecular weight of ionomycin free acid is 709.01 g/mol PubChem compound record
• The product description states that ionomycin transfers calcium ions between aqueous and organic phases, supporting its classification as an ionophore product information
• The stated purity is at least 95%, and the product is supplied as a solution in ethanol product information
• The reference study reports that FAISL is enriched among FAK-interacting long noncoding RNAs and is frequently overexpressed in triple-negative breast cancer tissues Zhang et al., Advanced Science, DOI 10.1002/advs.202407493
• The reference study reports that FAISL increases FAK protein abundance without changing FAK messenger RNA and blocks Calpain 2-mediated FAK proteolysis Zhang et al., Advanced Science, DOI 10.1002/advs.202407493
• The reference study reports that reduction-responsive nanoparticles carrying FAISL-directed siRNA inhibited tumor growth and metastasis in triple-negative breast cancer mouse models Zhang et al., Advanced Science, DOI 10.1002/advs.202407493

The benchmark evidence has two different layers. Product documentation supports chemical identity, formulation, handling, and stated ionophore activity. The peer-reviewed study supports the FAISL–FAK–Calpain 2 mechanism in TNBC models. It should not be cited as evidence that ionomycin was used in, or validated by, that study.

Applications, Limits & Misconceptions

Ionomycin free acid can support calcium-signaling experiments in cultured cells and membrane systems. Suitable endpoints include calcium flux, calcium-dependent protein responses, adhesion phenotypes, cytoskeletal organization, and cell survival. The experimental question should specify whether calcium is being used as a trigger, a perturbation, or a mechanistic control.

The product dossier describes in vivo mammalian oocyte activation and embryonic development promotion as applications. It also describes use in clinical fertility contexts involving decreased ovarian reserves. These statements describe reported applications in product information. They do not make this research reagent a diagnostic or medical product, and they do not replace institutional, regulatory, or clinical oversight.

Why this cross-domain matters, maturity, and limitations

Calcium-ionophore work in reproductive biology and FAISL–FAK work in TNBC address different biological systems. The reproductive application concerns oocyte activation and subsequent developmental competence. The cancer reference concerns lncRNA-mediated FAK stabilization, adhesion, and metastasis. The bridge between them is a testable calcium-signaling hypothesis, not an established therapeutic connection.

A mature cross-domain conclusion is therefore limited: ionomycin can be used to perturb calcium, while the reference paper defines a separate FAK-proteolysis axis. A hypothesis-driven TNBC experiment could test whether calcium perturbation changes FAK stability or Calpain 2-sensitive cleavage. Such a result would require direct measurement of calcium, FAK protein, proteolysis, viability, and relevant controls. It should not be interpreted as evidence that ionomycin targets FAISL.

Common Pitfalls or Misconceptions

• Misconception: ionomycin is a receptor agonist. It is an ion carrier. It does not reproduce the full signaling pattern of a physiological receptor ligand.
• Misconception: a calcium rise proves a specific pathway mechanism. Calcium elevation is a proximal readout. It does not by itself prove FAK cleavage, FAISL regulation, differentiation, or apoptosis.
• Misconception: selective means cell-type selective. The product description supports calcium-ionophore activity, not selective delivery to a particular tissue or tumor.
• Misconception: the reagent is a clinical treatment. The product is intended for scientific research only and is not recommended for diagnostic or medical use.
• Misconception: any solvent or storage format is equivalent. The supplied formulation is an ethanol solution, and long-term storage in solution form is not recommended by the product information.

Workflow Integration & Parameters

Protocol Parameters

• Material identity: Confirm CAS 56092-81-0, formula C₄₁H₇₂O₉, and the product lot before preparing an assay; the listed molecular weight is 709.01 g/mol.
• Solvent: Use the supplied ethanol formulation or a validated DMSO preparation when compatible with the assay; include a vehicle-matched control because solvent effects can alter cell behavior.
• Concentration selection: Establish a laboratory pilot range rather than importing a universal dose; response depends on cell type, extracellular calcium, exposure duration, and assay endpoint.
• Calcium readout: Record baseline signal before addition and define the post-addition observation window in advance; pair the calcium measurement with a viability or membrane-integrity measurement.
• FAK–TNBC workflow: If testing the FAISL hypothesis, measure FAK protein abundance and proteolysis alongside calcium, adhesion, and survival endpoints; treat any association as preliminary until directly reproduced.
• Storage: Keep the material desiccated at -20°C according to the product information; avoid long-term storage after solution preparation.
• Shipping: Small-molecule shipment may use blue ice; inspect the received container and document lot, condition, and storage transfer.

The linked article FAISL lncRNA Blocks FAK Degradation to Drive TNBC Metastasis focuses on the lncRNA mechanism and tumor phenotypes. This article extends that discussion by defining ionomycin as a calcium perturbation tool rather than presenting it as a demonstrated FAISL intervention.

The related guide Ionomycin Free Acid in FAK–TNBC Research connects ionomycin with FAK-oriented experiments. This article clarifies the evidence boundary: the cited TNBC paper supports FAISL-mediated FAK stabilization, while product documentation supports ionophore activity and handling.

Conclusion & Outlook

Ionomycin free acid is a practical calcium ionophore for controlled calcium ion transport experiments. Its reported identity, formulation, purity, solubility, and storage requirements are defined by product documentation. Its use in oocyte activation is distinct from the FAISL–FAK mechanism described in TNBC.

The most defensible outlook is mechanistic and experimental. Researchers can use ionomycin to ask whether a defined calcium perturbation changes FAK stability, adhesion, or survival in a TNBC model. The reference study requires those outcomes to be interpreted through FAISL and Calpain 2 biology, with direct calcium and proteolysis measurements. Any therapeutic or clinical conclusion would require evidence beyond the cited product information and reference study.